![\"\"](\"https:\/\/www.hashtag.al\/wp-content\/uploads\/2024\/08\/3b4289f68601a7d4fc34fcbd23afccb26d080010.png\")
<\/p>\n<\/p>\n
Steve Haycock e kishte hequr pjes\u00ebn m\u00eb t\u00eb madhe t\u00eb zorr\u00ebs s\u00eb trash\u00eb vitin e kaluar, por mjek\u00ebt i kan\u00eb th\u00ebn\u00eb 43-vje\u00e7arit se kanceri i tij n\u00eb zorr\u00eb ka shum\u00eb gjasa t\u00eb kthehet – p\u00ebrve\u00e7 n\u00ebse nj\u00eb prov\u00eb e personalizuar e nj\u00eb vaksine jep rezultat.<\/span><\/p>\n Produkti \u00ebsht\u00eb b\u00ebr\u00eb nga prodhuesi gjerman i vaksinave t\u00eb Covid-19, BioNTech, q\u00eb ka identifikuar proteina specifike p\u00ebr mutacionet n\u00eb qelizat e tij t\u00eb kancerit dhe ka krijuar nj\u00eb vaksin\u00eb q\u00eb do ushqej\u00eb sistemin e tij imunitar p\u00ebr t\u00eb sulmuar tumoret e rinj q\u00eb i p\u00ebrmbajn\u00eb ato.<\/span><\/p>\n \u201cM\u00eb ka dh\u00ebn\u00eb shum\u00eb besim t\u00eb jem n\u00eb k\u00ebt\u00eb prov\u00eb,\u201d<\/em> tha ai.<\/span><\/p>\n “Un\u00eb jam n\u00eb k\u00ebto pozita p\u00ebr shkak t\u00eb s\u00ebmundjes, por gjithsesi ndihem i privilegjuar.”<\/em><\/span><\/p>\n BioNTech dhe rivali amerikan p\u00ebr vaksin\u00ebn kund\u00ebr koronavirusit Moderna, aksionet e t\u00eb cilave kan\u00eb r\u00ebn\u00eb me rreth 80 p\u00ebrqind q\u00eb nga kulmi i tyre i pandemis\u00eb n\u00eb vitin 2021, kan\u00eb v\u00ebn\u00eb bast me vaksinat e kancerit p\u00ebr t\u00eb ringjallur pasurin\u00eb. Duke p\u00ebrdorur teknologjin\u00eb mRNA pas produkteve t\u00eb tyre Covid, ata shpresojn\u00eb t\u00eb p\u00ebrmir\u00ebsojn\u00eb n\u00eb m\u00ebnyr\u00eb drastike rezultatet dhe t\u00eb udh\u00ebheqin nj\u00eb fush\u00eb t\u00eb re t\u00eb kujdesit ndaj kancerit.<\/span><\/p>\n Por jan\u00eb vet\u00ebm dit\u00ebt e para p\u00ebr teknologjin\u00eb e personalizuar t\u00eb vaksinave dhe shum\u00eb pengesa mbeten. B\u00ebrja e nj\u00eb vaksine t\u00eb personalizuar p\u00ebr \u00e7do pacient do jet\u00eb e kushtueshme dhe do shoq\u00ebrohet me sfida t\u00eb zinxhir\u00ebve t\u00eb furnizimit, nd\u00ebrkoh\u00eb q\u00eb grupet farmaceutike po \u00e7ojn\u00eb p\u00ebrpara vazhdimisht lloje t\u00eb tjera barnash n\u00eb fush\u00ebn gjithnj\u00eb konkurruese kund\u00ebr kancerit.<\/span><\/p>\n Nd\u00ebrsa “\u00ebsht\u00eb shum\u00eb t\u00ebrheq\u00ebse dhe shum\u00eb emocionuese”, tha Miranda Payne, nj\u00eb specialiste e melanom\u00ebs q\u00eb drejton nj\u00eb prov\u00eb t\u00eb vaksin\u00ebs Moderna n\u00eb Spitalin Churchill t\u00eb Oksfordit, “\u00ebsht\u00eb pak e v\u00ebshtir\u00eb t\u00eb shoh\u00ebsh se si do e p\u00ebrshtat\u00ebsh at\u00eb p\u00ebr k\u00ebdo q\u00eb mund t\u00eb ket\u00eb nevoj\u00eb”.<\/span><\/p>\n Disa kompani jan\u00eb p\u00ebrpjekur t\u00eb zhvillojn\u00eb lloje t\u00eb ndryshme t\u00eb vaksin\u00ebs s\u00eb kancerit vitet e fundit, por produktet nuk kan\u00eb mundur t\u00eb nxisin nj\u00eb p\u00ebrgjigje efektive ndaj tumoreve, ve\u00e7an\u00ebrisht n\u00eb kanceret e avancuar n\u00eb faz\u00ebn e fundit kur sistemi imunitar \u00ebsht\u00eb tashm\u00eb i dob\u00ebt.<\/span><\/p>\n “Vaksinat kan\u00eb qen\u00eb historikisht nj\u00eb investim i mrekulluesh\u00ebm,”<\/em> tha Marek Poszepczynski, nj\u00eb ekspert onkologjik n\u00eb Trustin Nd\u00ebrkomb\u00ebtar t\u00eb Bioteknologjis\u00eb.<\/span><\/p>\n “Kanceret jan\u00eb shum\u00eb, shum\u00eb t\u00eb aft\u00eb p\u00ebr t’i shp\u00ebtuar sistemit imunitar.”<\/em><\/span><\/p>\n BioNTech dhe Moderna shpresojn\u00eb t\u00eb ken\u00eb sukses aty ku t\u00eb tjer\u00ebt kan\u00eb d\u00ebshtuar nd\u00ebrsa k\u00ebrkojn\u00eb t\u00eb zhvillojn\u00eb portofol t\u00eb gjer\u00eb t\u00eb trajtimeve t\u00eb kancerit. T\u00eb mb\u00ebshtetur nga t\u00eb ardhurat e fituara nga Covid-19, t\u00eb dy shpenzuan shuma rekord p\u00ebr k\u00ebrkime dhe zhvillim vitin e kaluar.<\/span><\/p>\n Produkti i BioNTech, i disponuesh\u00ebm p\u00ebr Haycock p\u00ebrmes nj\u00eb prove t\u00eb NHS, ka vite q\u00eb nga komercializimi. Ila\u00e7i i Moderna p\u00ebr melanom\u00ebn, nj\u00eb lloj kanceri i l\u00ebkur\u00ebs q\u00eb mund t\u00eb p\u00ebrhapet n\u00eb zona t\u00eb tjera t\u00eb trupit, u zhvillua me Merck dhe \u00ebsht\u00eb n\u00eb prova m\u00eb t\u00eb p\u00ebrparuara.<\/span><\/p>\n Nd\u00ebrsa mRNA i m\u00ebsoi sistemit imunitar t\u00eb njoh\u00eb dhe t\u00eb luftoj\u00eb Covid-19, ai mund t\u00eb udh\u00ebzoj\u00eb qelizat imune t\u00eb njohin proteinat e njohura si neoantigjene q\u00eb jan\u00eb t\u00eb ve\u00e7anta p\u00ebr mutacionet n\u00eb kancerin e nj\u00eb individi.<\/span><\/p>\n \u00c7do injeksion Moderna \u00ebsht\u00eb b\u00ebr\u00eb me porosi, me tumorin e secilit pacient t\u00eb renditur gjenomikisht p\u00ebr t\u00eb zgjedhur 34 neoantigjenet m\u00eb t\u00eb p\u00ebrshtatshme. Vaksina m\u00eb pas drejton sistemin imunitar t\u00eb njoh\u00eb k\u00ebto neoantigjene dhe t\u00eb sulmoj\u00eb qelizat e ardhshme t\u00eb kancerit q\u00eb i p\u00ebrmbajn\u00eb ato.<\/span><\/p>\n Produkti BioNTech i p\u00ebrdorur p\u00ebr trajtimin e Haycock \u00ebsht\u00eb duke u zhvilluar bashk\u00eb me deg\u00ebn e Roche Genentech dhe funksionon n\u00eb m\u00ebnyr\u00eb t\u00eb ngjashme, me deri n\u00eb 20 neoantigjen\u00eb t\u00eb zgjedhur.<\/span><\/p>\n Megjith\u00ebse fitoi\u00a0 r\u00ebnd\u00ebsi globale p\u00ebrmes Covid, fokusi kryesor i BioNTech q\u00eb kur u themelua n\u00eb 2008 ka qen\u00eb kanceri.<\/span><\/p>\n \u201cPersonalizimi i vaksinave tona mRNA \u00ebsht\u00eb risia jon\u00eb m\u00eb e r\u00ebnd\u00ebsishme\u201d<\/em>, tha Ugur Sahin, shefi ekzekutiv, p\u00ebr Financial Times.<\/span><\/p>\n Shefi ekzekutiv i Moderna, St\u00e9phane Bancel kujtoi se si i tha stafit von\u00eb gjat\u00eb pandemis\u00eb se “10 vjet nga tani, njer\u00ebzit do ken\u00eb harruar at\u00eb q\u00eb b\u00ebm\u00eb p\u00ebr bot\u00ebn gjat\u00eb pandemis\u00eb, sepse ne do njihemi si nj\u00eb nga kompanit\u00eb m\u00eb me ndikim t\u00eb produkteve kund\u00ebr kancerit”.<\/span><\/p>\n T\u00eb dh\u00ebnat pozitive n\u00eb qershor nga nj\u00eb prov\u00eb n\u00eb faz\u00ebn e mesme t\u00eb kancerit t\u00eb l\u00ebkur\u00ebs treguan se nj\u00eb vaksin\u00eb e personalizuar mund t\u00eb jet\u00eb m\u00eb af\u00ebr se kurr\u00eb.<\/span><\/p>\n “Disa investitor\u00eb jan\u00eb skeptik\u00eb, por ky \u00ebsht\u00eb nj\u00eb biznes shkencor,”<\/em> shtoi Bancel.<\/span><\/p>\n Mes nj\u00eb grupi prej 157 pacient\u00ebsh me melanoma n\u00eb faz\u00ebn e von\u00eb t\u00eb trajtuar me imunoterapin\u00eb e suksesshme t\u00eb kancerit t\u00eb Merck Keytruda, rreziku i vdekjes ose p\u00ebrs\u00ebritja e s\u00ebmundjes ra 49 p\u00ebr qind n\u00eb mesin e atyre q\u00eb mor\u00ebn gjithashtu vaksin\u00ebn Moderna. Moderna tani po ec\u00ebn p\u00ebrpara me provat n\u00eb fazat e vona t\u00eb kancerit.<\/span><\/p>\n Kombinimi i produkteve me trajtime t\u00eb tilla si Keytruda mund t\u00eb jet\u00eb \u00e7el\u00ebsi p\u00ebr realizimin e potencialit t\u00eb vaksinave.<\/span><\/p>\n Ila\u00e7i i Merck-ut \u00ebsht\u00eb m\u00eb i suksesshmi nga nj\u00eb val\u00eb imunoterapie t\u00eb njohura si frenuesit e \u201cpikave t\u00eb kontrollit\u201d. Miratuar p\u00ebr her\u00eb t\u00eb par\u00eb nga Administrata e Ushqimit dhe Barnave (FDA) t\u00eb SHBA-s\u00eb n\u00eb vitin 2014 p\u00ebr pacient\u00ebt me melanoma t\u00eb avancuara, Keytruda tani p\u00ebrdoret kund\u00ebr 17 llojeve t\u00eb kancerit, duke p\u00ebrfshir\u00eb kancerin e gjirit, mushk\u00ebrive, gjakut dhe l\u00ebkur\u00ebs. Ishte ila\u00e7i m\u00eb i shitur n\u00eb bot\u00eb vitin e kaluar me 25 miliard\u00eb dollar\u00eb t\u00eb ardhura.<\/span><\/p>\n Frenuesit “heqin frenat” n\u00eb qelizat e sistemit imunitar q\u00eb i ndalojn\u00eb ata t\u00eb sulmojn\u00eb tumoret, tha La\u00ebrence Young, nj\u00eb profesor onkologjie n\u00eb Universitetin e \u00cbar\u00ebick, nd\u00ebrsa vaksinat m\u00eb pas drejtojn\u00eb qelizat imune p\u00ebr t\u00eb synuar kancerin.<\/span><\/p>\n Nd\u00ebrsa vet\u00ebm 20-40 p\u00ebr qind e pacient\u00ebve u p\u00ebrgjigjen ila\u00e7eve, ekspert\u00ebt thon\u00eb se veprimi i dyfisht\u00eb i vaksinave mund ta rris\u00eb k\u00ebt\u00eb num\u00ebr.<\/span><\/p>\n “Shkenc\u00ebrisht, ka shum\u00eb kuptim t’i kombinosh ato,”<\/em> tha Peter Kiener, nj\u00eb investitor n\u00eb ICG Life Sciences, i cili \u00ebsht\u00eb nj\u00eb ekspert onkologjik.<\/span><\/p>\n Steve Haycock merr pjes\u00eb n\u00eb nj\u00eb prov\u00eb t\u00eb vaksin\u00ebs s\u00eb kancerit n\u00eb spitalin Queen Elizabeth n\u00eb Birmingham, Britani<\/em><\/span><\/p><\/div>\n \u201cN\u00ebse mund t\u00eb shtoni nj\u00eb vaksin\u00eb q\u00eb \u00ebsht\u00eb e tolerueshme, mund ta ndryshoni at\u00eb shkall\u00eb p\u00ebrgjigjeje nga 20-30 n\u00eb 50-60 p\u00ebr qind t\u00eb pacient\u00ebve. At\u00ebher\u00eb v\u00ebrtet mund t\u00eb keni nj\u00eb ndikim t\u00eb jasht\u00ebzakonsh\u00ebm n\u00eb s\u00ebmundje.\u201d<\/em><\/span><\/p>\n BioNTech po provon gjithashtu nj\u00eb vaksin\u00eb t\u00eb personalizuar t\u00eb melanom\u00ebs q\u00eb do dor\u00ebzohet s\u00eb bashku me Keytruda, por po zhvillon nj\u00eb tjet\u00ebr injeksion kund\u00ebr melanom\u00ebs q\u00eb do p\u00ebrdoret me nj\u00eb frenues t\u00eb zhvilluar nga Regeneron. Kompania tha muajin e kaluar se tumoret ishin tkurrur m\u00eb shum\u00eb te pacient\u00ebt q\u00eb merrnin vaksin\u00ebn sesa te ata me trajtim standard, megjith\u00ebse nuk ka zbuluar rezultate t\u00eb holl\u00ebsishme.<\/span><\/p>\n Qasja e personalizuar ka t\u00eb meta.<\/span><\/p>\n \u201c\u00cbsht\u00eb shum\u00eb e shtrenjt\u00eb n\u00ebse duhet t\u00eb marr\u00ebsh mostr\u00ebn e tumorit, ta rendit\u00ebsh e analizosh at\u00eb dhe t\u00eb b\u00ebsh nj\u00eb vaksin\u00eb me porosi,\u201d<\/em> tha Young.<\/span><\/p>\n \u201cNd\u00ebrsa qasja e individualizuar \u00ebsht\u00eb emocionuese dhe do t\u00eb jet\u00eb prov\u00eb e parimit t\u00eb ndjekur, un\u00eb dyshoj se do ket\u00eb nj\u00eb qasje m\u00eb t\u00eb p\u00ebrgjith\u00ebsuar.\u201d<\/em><\/span><\/p>\n BioNTech po i provon t\u00eb dyja strategjit\u00eb: produkti i saj melanom\u00ebs me Regeneron \u00ebsht\u00eb nj\u00eb ila\u00e7 \u00a0q\u00eb p\u00ebrdor vet\u00ebm kat\u00ebr antigjene melanoma, t\u00eb pakt\u00ebn nj\u00ebri prej t\u00eb cil\u00ebve \u00ebsht\u00eb i pranish\u00ebm n\u00eb 90 p\u00ebr qind t\u00eb melanomave. Ky mund t\u00eb jet\u00eb m\u00eb i lir\u00eb p\u00ebr t’u prodhuar, por m\u00eb pak i synuar se produkti Moderna.<\/span><\/p>\n \u00cbsht\u00eb nj\u00eb nga tet\u00eb provat e vijueshme p\u00ebr vaksinat e kancerit mRNA q\u00eb BioNTech po kryen, duke p\u00ebrfshir\u00eb vaksinat e personalizuara p\u00ebr kancerin e mushk\u00ebrive, pankreasit dhe t\u00eb zorr\u00ebs s\u00eb trash\u00eb.<\/span><\/p>\n Por Moderna ka t\u00eb ngjar\u00eb t\u00eb jet\u00eb e para n\u00eb treg. Pasi ka treguar potencialin e vaksin\u00ebs s\u00eb saj kund\u00ebr melanom\u00ebs, kompania ka nisur provat e faz\u00ebs s\u00eb tret\u00eb duke testuar vaksin\u00ebn p\u00ebr llojin m\u00eb t\u00eb zakonsh\u00ebm t\u00eb kancerit t\u00eb mushk\u00ebrive dhe nj\u00eb form\u00eb tjet\u00ebr t\u00eb kancerit t\u00eb l\u00ebkur\u00ebs, si dhe prova t\u00eb faz\u00ebs s\u00eb hershme n\u00eb kancerin e veshkave dhe fshik\u00ebz\u00ebs, midis t\u00eb tjer\u00ebve.<\/span><\/p>\n Ajo gjithashtu planifikon t\u00eb studioj\u00eb vaksin\u00ebn e saj t\u00eb kancerit si nj\u00eb trajtim t\u00eb pavarur p\u00ebr pacient\u00ebt me kancer n\u00eb faz\u00ebn e hershme, pa p\u00ebrdorur Keytruda si nj\u00eb terapi t\u00eb dyfisht\u00eb.<\/span><\/p>\n \u201cAmbicia q\u00eb kemi me Merck \u00ebsht\u00eb q\u00eb ta \u00e7ojm\u00eb vaksin\u00ebn e kancerit n\u00eb t\u00eb gjitha vendet dhe ta b\u00ebjm\u00eb at\u00eb po aq t\u00eb madhe sa jan\u00eb b\u00ebr\u00eb frenuesit\u201d<\/em>, tha Stephen Hoge, presidenti i Moderna-s q\u00eb drejton p\u00ebrpjekjet e saj k\u00ebrkimore dhe zhvillimore.<\/span><\/p>\n Nj\u00eb vaksin\u00eb prov\u00eb kund\u00ebr kancerit nga BioNTech q\u00eb mund t\u00eb individualizohet p\u00ebr tumorin e nj\u00eb pacienti specifik<\/span><\/em><\/p><\/div>\n N\u00eb Oksford, Payne ka ndihmuar pacient\u00ebt q\u00eb kan\u00eb pasur nj\u00eb operacion t\u00eb melanom\u00ebs t\u00eb marrin pjes\u00eb n\u00eb prov\u00ebn e faz\u00ebs s\u00eb tret\u00eb nga Moderna.<\/span><\/p>\n \u201cKa pasur interes t\u00eb madh p\u00ebr t\u00eb\u201d<\/em>, tha ajo, duke shtuar se Moderna e arriti q\u00ebllimin e saj t\u00eb rekrutimit p\u00ebr pjes\u00ebmarr\u00ebsit n\u00eb qershor, shum\u00eb p\u00ebrpara objektivit origjinal t\u00eb mesit t\u00eb vitit 2025.<\/span><\/p>\n Por p\u00ebrvoja e Payne tregon edhe sfida t\u00eb tjera p\u00ebr prodhuesit e vaksinave. Ajo tha se nj\u00eb n\u00eb kat\u00ebr pacient\u00eb t\u00eb sugjeruar nga ajo ishte larguar p\u00ebr shkak t\u00eb problemeve me mostrat e tumorit dhe identifikimit t\u00eb pamjaftuesh\u00ebm t\u00eb neoantigjeneve p\u00ebr t\u00eb b\u00ebr\u00eb vaksinat.<\/span><\/p>\n P\u00ebr t\u00eb forcuar zinxhirin e saj t\u00eb furnizimit, Moderna ka investuar 322 milion\u00eb dollar\u00eb n\u00eb nj\u00eb struktur\u00eb t\u00eb prodhimit t\u00eb vaksinave n\u00eb shtetin e saj t\u00eb Massachusetts. BioNTech po investon gjithashtu n\u00eb objekte t\u00eb reja pran\u00eb selis\u00eb s\u00eb saj n\u00eb Mainz, Gjermani, q\u00eb shpreson t’i hap\u00eb deri n\u00eb fund t\u00eb vitit.<\/span><\/p>\n Por Kyle Holen, kreu i onkologjis\u00eb n\u00eb Moderna, pranoi se procesi i analizimit t\u00eb tumoreve mund t\u00eb ishte akoma m\u00eb i leht\u00eb. Moderna aktualisht nuk mund t\u00eb p\u00ebrdor\u00eb t\u00eb dh\u00ebnat e sekuenc\u00ebs nga biopsia e nj\u00eb pacienti p\u00ebr t\u00eb diagnostikuar kancerin e tyre, q\u00eb do thot\u00eb se duhet t\u00eb kryhet nj\u00eb grup i dyt\u00eb provash.<\/span><\/p>\n Sahin tha se ai priste q\u00eb ila\u00e7et t\u00eb ishin m\u00eb t\u00eb shtrenjta se imunoterapit\u00eb ekzistuese dhe se \u00e7mimet do t\u00eb duhej t\u00eb justifikoheshin duke parandaluar tendosjet e ardhshme n\u00eb sistemet e kujdesit sh\u00ebndet\u00ebsor.<\/span><\/p>\n \u201cMund t\u00eb jet\u00eb e shtrenjt\u00eb vet\u00ebm n\u00ebse adreson me t\u00eb v\u00ebrtet\u00eb nj\u00eb nevoj\u00eb t\u00eb lart\u00eb mjek\u00ebsore dhe n\u00ebse redukton kostot e rrjedh\u00ebs s\u00eb poshtme q\u00eb lidhen, p\u00ebr shembull, duke parandaluar kancerin metastatik,\u201d<\/em> tha ai.<\/span><\/p>\n Por disa ekspert\u00eb shtuan se kishte alternativa q\u00eb gjithashtu mund t\u00eb parandalonin kthimin e kancerit, potencialisht me nj\u00eb kosto m\u00eb t\u00eb ul\u00ebt.<\/span><\/p>\n Nj\u00eb studim i vitit 2023 zbuloi se dh\u00ebnia e Keytrudas pacient\u00ebve me melanoma t\u00eb avancuara para dhe pas operacionit, n\u00eb vend t\u00eb dh\u00ebnies vet\u00ebm pas operacionit, gjithashtu mund t\u00eb vonoj\u00eb p\u00ebrs\u00ebritjen e kancerit. Tre t\u00eb kat\u00ebrtat e pacient\u00ebve q\u00eb e mor\u00ebn at\u00eb para dhe pas nuk kishin kancer brenda dy viteve, kundrejt gjysm\u00ebse q\u00eb e mor\u00ebn ila\u00e7in vet\u00ebm pas operacionit.<\/span><\/p>\n Merck gjithashtu pranon se ka kufizime p\u00ebr vaksinat.<\/span><\/p>\n Nj\u00eb studiues n\u00eb Moderna HQ n\u00eb Kembrixh, Massachusetts. Kompania po k\u00ebrkon m\u00ebnyra p\u00ebr t\u00eb zgjeruar vaksinat e mRNA q\u00eb nga pandemia e Coronavirusit<\/em><\/span><\/p><\/div>\n \u201cThembra e Akilit e k\u00ebsaj terapie t\u00eb ve\u00e7ant\u00eb \u00ebsht\u00eb se ajo k\u00ebrkon q\u00eb sistemi imunitar t\u00eb mbetet i paprekur n\u00eb m\u00ebnyr\u00eb q\u00eb ata t\u00eb mund t\u00eb krijojn\u00eb nj\u00eb p\u00ebrgjigje imune\u201d<\/em>, tha Eliav Barr, shefi mjek\u00ebsor i Merck, q\u00eb do t\u00eb thot\u00eb se pacient\u00ebt m\u00eb t\u00eb rinj do kishin m\u00eb shum\u00eb gjasa t\u00eb p\u00ebrfitonin nga ila\u00e7i.<\/span><\/p>\n Dhe pavar\u00ebsisht nga t\u00eb dh\u00ebnat mbres\u00ebl\u00ebn\u00ebse t\u00eb melanom\u00ebs, ekspert\u00ebt mbeten n\u00eb dyshim se sa do jen\u00eb t\u00eb dobishme vaksinat kund\u00ebr kancereve t\u00eb tjera ose si nj\u00eb trajtim i pavarur.<\/span><\/p>\n Sipas Elizabeth Jaffee, profesoresh\u00eb e onkologjis\u00eb n\u00eb Universitetin Johns Hopkins, melanoma \u00ebsht\u00eb nd\u00ebr kanceret me frekuenc\u00ebn m\u00eb t\u00eb lart\u00eb t\u00eb mutacioneve gjenetike, duke u v\u00ebn\u00eb n\u00eb sh\u00ebnjest\u00ebr t\u00eb imunoterapis\u00eb. Vaksinat mund t\u00eb mos jen\u00eb aq t\u00eb mira kund\u00ebr kancereve m\u00eb pak reagues ndaj imunitetit, tha ajo.<\/span><\/p>\n Nd\u00ebrkoh\u00eb, lojtar\u00ebt rival\u00eb t\u00eb farmacive po avancojn\u00eb gjithashtu trajtime alternative si terapit\u00eb CAR-T, nj\u00eb tjet\u00ebr produkt shum\u00eb i kushtuesh\u00ebm dhe i personalizuar ku qelizat imune t\u00eb pacient\u00ebve ose qelizat T, nxirren dhe modifikohen gjenetikisht p\u00ebr t\u00eb vrar\u00eb m\u00eb mir\u00eb qelizat e kancerit p\u00ebrpara se t\u00eb riinjektohen.<\/span><\/p>\n “Vaksinat e kancerit do duhet t\u00eb tregojn\u00eb se mund t\u00eb konkurrojn\u00eb kund\u00ebr rritjes s\u00eb konkurrenc\u00ebs,”<\/em> tha Susan Galbraith, drejtuese e k\u00ebrkimit dhe zhvillimit n\u00eb AstraZeneca, e cila po mb\u00ebshtet CAR-T dhe terapit\u00eb e qelizave.<\/span><\/p>\n Megjithat\u00eb, si BioNTech ashtu edhe Moderna kan\u00eb b\u00ebr\u00eb p\u00ebrparim t\u00eb r\u00ebnd\u00ebsish\u00ebm vitet e fundit. Pasi prova e faz\u00ebs 3 t\u00eb Moderna t\u00eb regjistrohet plot\u00ebsisht, kompania do aplikoj\u00eb te FDA-ja n\u00eb SHBA p\u00ebr nj\u00eb miratim t\u00eb p\u00ebrshpejtuar, tha Bancel, miratim q\u00eb mund t\u00eb vij\u00eb q\u00eb n\u00eb fillim t\u00eb vitit t\u00eb ardhsh\u00ebm.<\/span><\/p>\n Produktet e BioNTech do k\u00ebrkojn\u00eb m\u00eb shum\u00eb koh\u00eb p\u00ebr t’u avancuar, por Sahin tha se ai priste t\u00eb jet\u00eb n\u00eb gjendje t\u00eb nis\u00eb trajtime t\u00eb reja kund\u00ebr kancerit deri n\u00eb vitin 2026, me nj\u00eb vaksin\u00eb t\u00eb personalizuar q\u00eb do vij\u00eb p\u00ebrpara vitit 2030. Produktet, beson ai, do ken\u00eb ndikim t\u00eb ngjash\u00ebm si frenuesit si Keytruda.<\/span><\/p>\n \u201cNe nuk duhet t\u00eb harrojm\u00eb se ky nuk \u00ebsht\u00eb vet\u00ebm nj\u00eb produkt i ri, por nj\u00eb koncept i ri, nj\u00eb teknologji e re,\u201d<\/em> tha ai.<\/span><\/p>\n \u201cVaksinat jan\u00eb nj\u00eb nga trajtimet me skepticizmin m\u00eb t\u00eb madh, por shoh gjithnj\u00eb e m\u00eb shum\u00eb njer\u00ebz q\u00eb jan\u00eb entuziast\u00eb p\u00ebr to.\u201d<\/em><\/span><\/p>\n Nj\u00eb nga entuziast\u00ebt \u00ebsht\u00eb Haycock, i cili \u00ebsht\u00eb n\u00eb turin e tet\u00eb nga pothuajse 20 n\u00eb t\u00eb cilat ai do marr\u00eb vaksin\u00ebn.<\/span><\/p>\n “Kam humbur \u00e7aste nga jeta ime duke menduar se \u00ebsht\u00eb vet\u00ebm \u00e7\u00ebshtje kohe para se kanceri im t\u00eb p\u00ebrfshij\u00eb t\u00eb menduarit tim, po n\u00ebse kjo funksionon, nuk do m\u00eb duhet domosdoshm\u00ebrisht t\u00eb shqet\u00ebsohem shum\u00eb,”<\/em> tha ai.<\/span><\/p>\n![\"\"](\"https:\/\/www.hashtag.al\/wp-content\/uploads\/2024\/08\/4efc71fd1bc9d9d8609171856db8c2e55f248fcd.png\")
<\/p>\n![\"\"](\"https:\/\/www.hashtag.al\/wp-content\/uploads\/2024\/08\/206381ca223966455dd60a522808bddea74d508c.png\")
<\/p>\n![\"\"](\"https:\/\/www.hashtag.al\/wp-content\/uploads\/2024\/08\/b308fdec862488dc8b620a232020f803be965a91.png\")
![\"\"](\"https:\/\/www.hashtag.al\/wp-content\/uploads\/2024\/08\/27f7298defaaa943c5b36d53fd243e175592e538.png\")
![\"\"](\"https:\/\/www.hashtag.al\/wp-content\/uploads\/2024\/08\/3cbcba65f5d320854250c7529b2a9259361a67e3.png\")